Developer docs
API playgroundTry for free, no card

Search company profiles

C2 PHARMA

Full company profile

uuid000iv57

Namestring
C2 PHARMA
Legal namestring
C-squared PHARMA Limited / C-squared PHARMA S.à r.l.
Websiteurl
c2pharma.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

C2 PHARMA is a privately-held pharmaceutical group established in 2014, headquartered in Cork, Ireland with its primary operating entity in Luxembourg. The company manufactures and distributes active pharmaceutical ingredients (APIs) and complex chemical compounds derived from natural (phytochemical) and synthetic origins, specializing in ophthalmic and niche APIs that are difficult to manufacture or face supply chain disruptions. Its 17-product portfolio includes ophthalmic APIs (atropine sulfate, bimatoprost, brimonidine tartrate, cyclopentolate hydrochloride, dorzolamide hydrochloride, homatropine hydrobromide, latanoprost, naphazoline hydrochloride, naphazoline nitrate, oxybuprocaine hydrochloride, pilocarpine hydrochloride, pilocarpine nitrate, timolol maleate, tropicamide) and cardiac APIs (digoxin, digoxin micronized), with multiple products on the WHO List of Essential Medicines.

The company's core technology is a virtual manufacturing model that coordinates a curated network of contract manufacturing organizations (CMOs) including Laurus Labs in India, Nobilus Ent in Poland, SMS Lifesciences, and Anidro do Brasil, with proprietary quality oversight including annual audits and quality assurance agreements. This model is supplemented by wholly-owned affiliates: ASM Research Chemicals GmbH (Hannover) for R&D-scale synthesis of complex organic molecules and PNA monomers, and Logistics4Pharma for GDP-compliant cold chain storage and global air freight. C2 PHARMA holds an extensive portfolio of regulatory filings across the US (US-DMF), Europe (CEP), China (C-DMF), Taiwan (T-DMF), South Korea (K-DMF), Brazil, and Mexico, with several CEP approvals noted as first or second of their kind.

C2 PHARMA generates revenue through direct sales of APIs and drug products to approximately 200 pharmaceutical companies globally, including top big pharma firms, with a sales-led go-to-market focused on ophthalmic and niche API buyers. Additional revenue streams include API lifecycle management services (acquiring and managing non-core or difficult-to-manufacture APIs on behalf of pharmaceutical clients) and affiliated cold chain logistics services. Pricing is quote-based and not publicly disclosed. The company is wholly owned by founder and CEO Andrew Badrot, with no disclosed institutional venture capital or private equity backing, and operates through legal entities in Ireland, Luxembourg, the United States, Germany, and India.

Short descriptiontext

C2 PHARMA is a privately-held pharmaceutical group that manufactures and distributes niche ophthalmic and cardiac active pharmaceutical ingredients (APIs) via a virtual CMO network, serving approximately 200 pharmaceutical companies globally through direct sales and multi-jurisdiction regulatory filings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCork, Ireland
HQ citystring
Cork
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic APIs, active pharmaceutical ingredients, niche API manufacturing, phytochemical APIs, API lifecycle management
Industry6 codes
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYTLAIACAD
Pharmaceutical & Life Sciences Warehousing (GDP-Compliant)
Transportation & Logistics/Third-Party & Fourth-Party Logistics (3PL/4PL) / Contract Logistics/Warehousing Operations & Contract Storage (Dedicated/Shared)
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Active Pharmaceutical Ingredients
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1API Manufacturing and Distribution
TypeOne Time License
Description

Manufacturing and distribution of active pharmaceutical ingredients (APIs) including ophthalmic APIs (atropine sulfate, bimatoprost, brimonidine tartrate, cyclopentolate hydrochloride, dorzolamide hydrochloride, homatropine hydrobromide, latanoprost, naphazoline hydrochloride, naphazoline nitrate, oxybuprocaine hydrochloride, pilocarpine hydrochloride, pilocarpine nitrate, timolol maleate, tropicamide) and cardiac APIs (digoxin, digoxin micronized). Direct sales to approximately 200 pharmaceutical companies globally.

c2pharma.com
2API Lifecycle Management Services
TypeProfessional Services
Description

Services to streamline pharmaceutical companies' product portfolios by acquiring and managing non-core, difficult-to-manufacture, or challenging-to-distribute APIs and drug products.

c2pharma.com
3Cold Chain Logistics
TypeManaged Services
Description

Customized cold chain and GDP-compliant transport and storage solutions through affiliate Logistics4Pharma.

c2pharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

C2 PHARMA manufactures and distributes Active Pharmaceutical Ingredients (APIs) and complex chemical compounds from natural and synthetic origins. The company operates a virtual manufacturing model combining contract manufacturing organizations (CMOs) with proprietary quality oversight, specializing in niche and ophthalmic APIs such as atropine sulfate, bimatoprost, digoxin, latanoprost, pilocarpine, and tropicamide for approximately 200 pharmaceutical customers globally. The company also offers API lifecycle management services and GDP-compliant cold chain logistics through affiliate Logistics4Pharma.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

C2 PHARMA is a pharmaceutical group established in 2014 that manufactures and distributes active pharmaceutical ingredients (APIs) and complex chemical compounds obtained from natural and synthetic origins. The company positions itself as a global leader in ophthalmic and niche APIs, offering 17 distinct API products including Bimatoprost, Brimonidine Tartrate, Cyclopentolate Hydrochloride, Digoxin, Dorzolamide Hydrochloride, Homatropine Hydrobromide, Homatropine Methylbromide, Latanoprost, Naphazoline Hydrochloride, Naphazoline Nitrate, Oxybuprocaine Hydrochloride, Pilocarpine Hydrochloride, Pilocarpine Nitrate, Timolol Maleate, and Tropicamide. The product portfolio spans ophthalmic APIs for glaucoma treatment and eye diagnostics, cardiac glycosides for heart conditions, and topical decongestants. Services include API Manufacturing and Distribution, API Lifecycle Management, and Pharma Logistics through affiliated company Logistics4Pharma offering GDP-compliant cold-chain transport and storage. The company maintains a direct sales presence across approximately 200 pharmaceutical customers globally including top pharmaceutical companies.

Product and service19 records
1Atropine Sulfate
CategoryActive Pharmaceutical Ingredient
Description

A naturally occurring phytochemical alkaloid originally identified in Atropa belladonna, used as an antidote for cholinergic drug and organophosphate poisoning, and for ophthalmic formulations as a cycloplegic pre-diagnostic agent and treatment for refractive and accommodative amblyopia. Sold to pharmaceutical manufacturers.

2Bimatoprost
CategoryActive Pharmaceutical Ingredient
Description

A synthetic amide analogue (prostamide) of prostaglandin F2α, used as first-line treatment for glaucoma in European Glaucoma Society guidelines, as 0.03% ophthalmic solution for ocular hypertension and glaucoma, and for eyelash hypotrichosis. Sold to ophthalmic pharmaceutical manufacturers.

3Brimonidine Tartrate
CategoryActive Pharmaceutical Ingredient
Description

A synthetic, highly selective third generation α2-adrenergic agonist used to reduce intraocular pressure through dual mechanism of reducing aqueous humour production and increasing uveoscleral outflow, approved in more than 50 countries. Sold to ophthalmic pharmaceutical manufacturers.

4Cyclopentolate Hydrochloride
CategoryActive Pharmaceutical Ingredient
Description

A synthetic muscarinic receptor antagonist developed in the 1950s, used as first-choice drug for cycloplegic refraction and diagnostic pupil dilation in patients of all ages, on WHO List of Essential Medicines. Sold to ophthalmic pharmaceutical manufacturers.

5Digoxin
CategoryActive Pharmaceutical Ingredient
Description

A cardiac glycoside extracted from Digitalis lanata leaves, used chronically in therapy of cardiac arrhythmias especially atrial fibrillation and heart failure, on WHO List of Essential Medicines. Sold to cardiovascular pharmaceutical manufacturers.

6Digoxin Micronized
CategoryActive Pharmaceutical Ingredient
Description

A micronized grade of cardiac glycoside extracted from Digitalis lanata leaves, developed to meet stringent specifications for particle size distribution less than 10 μm, used for cardiac arrhythmias and heart failure treatment. Sold to cardiovascular pharmaceutical manufacturers.

7Dorzolamide Hydrochloride
CategoryActive Pharmaceutical Ingredient
Description

A topical carbonic anhydrase inhibitor (CAI) belonging to sulfonamide derivatives, selectively inhibits carbonic anhydrase II, used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Sold to ophthalmic pharmaceutical manufacturers.

8Homatropine Hydrobromide
CategoryActive Pharmaceutical Ingredient
Description

A synthetic analogue of atropine prepared by esterification of mandelic acid with 3α-tropine, used as 2% or 5% ophthalmic solution to induce mydriasis and cycloplegia prior to retinoscopy, with effect 10 times weaker than atropine. Sold to ophthalmic pharmaceutical manufacturers.

9Homatropine Methylbromide
CategoryActive Pharmaceutical Ingredient
Description

A synthetic analog of atropine belonging to antimuscarinics, used to treat duodenal or stomach ulcers and intestinal problems, may be used to prevent nausea, vomiting, and motion sickness, and as sub-therapeutic amount in opioid formulations. Sold to pharmaceutical manufacturers.

10Latanoprost
CategoryActive Pharmaceutical Ingredient
Description

A rationally designed synthetic ester prodrug analogue of prostaglandin F2α (PGF2α), on WHO List of Essential Medicines and top 100 most commonly prescribed medications in the US, used for reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension. Sold to ophthalmic pharmaceutical manufacturers.

11Naphazoline Hydrochloride
CategoryActive Pharmaceutical Ingredient
Description

A white crystalline sympathomimetic amine compound, patented in 1934 and used primarily to relieve allergy symptoms and as decongestant, with CNS stimulant and blood vessel constrictor properties for reducing redness in minor eye irritations. Sold to pharmaceutical manufacturers.

12Naphazoline Nitrate
CategoryActive Pharmaceutical Ingredient
Description

A white crystalline powder developed in 1942 as nasal formulation for congestion, primarily used as topical nasal decongestant but also included in ophthalmic solutions to alleviate ocular redness and irritation. Sold to pharmaceutical manufacturers.

13Oxybuprocaine Hydrochloride
CategoryActive Pharmaceutical Ingredient
Description

A synthetic local anesthetic also known as benoxinate, first described in 1950, used in 0.4% ophthalmic solution for short ocular diagnostic and minor surgical procedures, with anesthetic activity ten times that of cocaine. Sold to ophthalmic pharmaceutical manufacturers.

14Pilocarpine Hydrochloride
CategoryActive Pharmaceutical Ingredient
Description

An agonist of muscarinic type cholinergic receptors, isolated from jaborandi leaves, used in eye drops for glaucoma treatment and as oral tablets for dry mouth and eyes caused by Sjögren's syndrome and salivary gland hypofunction from radiotherapy. Sold to ophthalmic pharmaceutical manufacturers.

15Pilocarpine Nitrate
CategoryActive Pharmaceutical Ingredient
Description

An agonist of muscarinic type cholinergic receptors derived from Pilocarpus microphyllus (Maranham Jaborandi), exclusive distribution by C2 PHARMA from Anidro do Brasil, used for chronic glaucoma treatment and to increase sweat secretion by iontophoresis in cystic fibrosis diagnostic devices. Sold to ophthalmic pharmaceutical manufacturers.

16Timolol Maleate
CategoryActive Pharmaceutical Ingredient
Description

A non-selective beta-adrenergic antagonist (β1 and β2) patented in 1978, used topically to reduce intraocular pressure in open-angle glaucoma or ocular hypertension, and systemically for hypertension, myocardial infarction, arrhythmias and migraine prophylaxis. Sold to ophthalmic pharmaceutical manufacturers.

17Tropicamide
CategoryActive Pharmaceutical Ingredient
Description

A fully synthetic non-selective muscarinic antagonist developed in the 1950s, on WHO List of Essential Medicines, used as 0.5% and 1% topical ophthalmic solution for mydriasis and cycloplegia in diagnostic procedures, and reported as diagnostic tool in Alzheimer's disease. Sold to ophthalmic pharmaceutical manufacturers.

18API Lifecycle Management Services
CategoryPharmaceutical Services
Description

Comprehensive end-to-end management of APIs from development through commercial supply, including regulatory filings, manufacturing oversight, and quality control. Services streamline pharmaceutical companies' product portfolios by acquiring and managing non-core, difficult-to-manufacture, or challenging-to-distribute APIs and drug products. Targeted at pharmaceutical manufacturers.

19GDP-Compliant Cold Chain Logistics
CategoryPharmaceutical Logistics
Description

Customized cold chain and GDP-compliant transport and storage solutions for APIs and pharmaceutical products, supporting temperature ranges of +2 to +8°C, +15 to +25°C, and -15 to -25°C. Operates 1000 m2 warehouse near Frankfurt Airport with validated temperature-controlled vehicles and IATA license for global air freight. Targeted at pharmaceutical manufacturers requiring temperature-controlled distribution.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-10-01
Description

Additional CMO partner added to strengthen manufacturing network and accelerate bringing R&D portfolio of ophthalmic products to commercial market.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2019-03-18
Description

Polish manufacturing partner for digoxin API acquired from Roche/Galenus Mannheim. C2 PHARMA is product owner; Nobilus is manufacturing partner and releasing entity. Provides parallel manufacturing for supply redundancy.

3Theracule AS
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2018-10-04
Description

Strategic partnership focused on supporting Theracule's new drug development programs for rare neurodevelopmental disorders. C2 PHARMA leads seed funding and provides GMP-compliant botanical extracts and APIs, regulatory support, and analytical sciences support through ASM Research Chemicals.

c2pharma.com
Strategic tierCoreTypeOthersAnnounced on2017-10-16
Description

Cold-chain logistics spin-off established by C2 PHARMA offering GDP-compliant transport and storage solutions for APIs and pharmaceutical products. Operates 1000 m2 warehouse near Frankfurt Airport with validated temperature-controlled vehicles and IATA license for global air freight.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2017-10-16
Description

R&D synthesis services company acquired by C2 PHARMA located in Hannover, Germany. Pioneer in synthesis of PNA (Peptide Nucleic Acid) Monomers and provides contract manufacturing for R&D-scale synthesis of complex organic molecules and impurities. Operates 600 m2 chemistry laboratory with 13 staff, 7 PhD chemists.

6Anidro do Brasil Extrações
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-10-16
Description

World's leading manufacturer of pilocarpine, exclusive distributor relationship with C2 PHARMA. Produces pilocarpine extracted from Jaborandi plant leaves (Pilocarpus microphyllus) native to northern Brazil.

c2pharma.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2017-10-02
Description

Indian-based API manufacturer and CMO partner. C2 PHARMA invested in dedicated digoxin manufacturing facility at Laurus Labs site in Vizag, India. Investment exceeded USD 5 million for 1800 m2 facility with annual production capacity exceeding global digoxin demand.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European specialty small-molecule API manufacturer spun out of Sanofi, serving branded and generic pharma with complex APIs across multiple therapeutic categories. Directly comparable to C2 PHARMA's small-molecule, multi-regulatory niche API model and customer base of top pharma companies.

TypeDirect peer
Description

Portugal-headquartered specialty CDMO with deep small-molecule API and ophthalmic expertise, including particle engineering for inhaled and ophthalmic dosage forms. Competes head-to-head with C2 PHARMA for complex API contracts and shares the same ophthalmic and niche-pharma customer profile.

TypeDirect peer
Description

Specialty small-molecule API manufacturer offering process R&D, scale-up, and commercial manufacturing across multiple therapeutic categories including ophthalmology. Operates a similar asset-and-virtual hybrid API model serving global pharma customers, comparable in product portfolio breadth and regulatory complexity.

TypeDirect peer
Description

India-headquartered API manufacturer and custom synthesis provider serving global generics and Big Pharma with complex small molecules. Comparable scale, generic/specialty API mix, US-DMF/CEP-heavy regulatory footprint, and ophthalmic API capabilities paralleling C2 PHARMA's commercial manufacturing model.

TypeDirect peer
Description

Global CDMO/API division of Piramal Pharma offering small-molecule API development, tech transfer and commercial manufacturing to branded and generic pharma. Overlaps with C2 PHARMA's virtual manufacturing strategy and global pharma customer base across ophthalmic, cardiovascular and specialty molecules.

TypeDirect peer
Description

Indian API and formulation manufacturer that operates C2 PHARMA's dedicated digoxin facility but also sells APIs independently into global generics and Big Pharma. Overlaps in small-molecule API manufacturing, CMO services, and the same ophthalmic/contract-manufacturing competitive space.

TypeDirect peer
Description

Specialty API/HPAPI CDMO business (now Veranova) offering complex small-molecule development and commercial manufacturing to global pharma. Comparable complexity, regulatory intensity, and customer profile to C2 PHARMA's niche-API commercial manufacturing model.

TypeDirect peer
Description

Italy-headquartered specialist in botanical-derived APIs and phytochemical extracts for pharma, with deep sustainability and traceability programs for natural-source ingredients. Direct mirror of C2 PHARMA's phytochemical expertise (pilocarpine, digoxin/Digitalis, atropine) and plant-derived API positioning.

TypeDirect peer
Description

Specialty peptide and small-molecule API manufacturer serving global pharma and ophthalmic customers with regulatory-grade peptides and complex actives. Comparable in niche positioning, regulatory depth (US-DMF, CEP) and GMP manufacturing across multiple therapeutic categories.

TypeBroad incumbent
Description

Large vertically integrated Indian generic manufacturer with significant ophthalmic API/formulation operations and global Big Pharma supply contracts. Competes broadly with C2 PHARMA in ophthalmic APIs but across a much wider product set and own-plant model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

C2 PHARMA

Active Pharmaceutical Ingredientsc2pharma.com

C2 PHARMA is a privately-held pharmaceutical group that manufactures and distributes niche ophthalmic and cardiac active pharmaceutical ingredients (APIs) via a virtual CMO network, serving approximately 200 pharmaceutical companies globally through direct sales and multi-jurisdiction regulatory filings.

What C2 PHARMA does

C2 PHARMA is a privately-held pharmaceutical group established in 2014, headquartered in Cork, Ireland with its primary operating entity in Luxembourg. The company manufactures and distributes active pharmaceutical ingredients (APIs) and complex chemical compounds derived from natural (phytochemical) and synthetic origins, specializing in ophthalmic and niche APIs that are difficult to manufacture or face supply chain disruptions. Its 17-product portfolio includes ophthalmic APIs (atropine sulfate, bimatoprost, brimonidine tartrate, cyclopentolate hydrochloride, dorzolamide hydrochloride, homatropine hydrobromide, latanoprost, naphazoline hydrochloride, naphazoline nitrate, oxybuprocaine hydrochloride, pilocarpine hydrochloride, pilocarpine nitrate, timolol maleate, tropicamide) and cardiac APIs (digoxin, digoxin micronized), with multiple products on the WHO List of Essential Medicines.

The company's core technology is a virtual manufacturing model that coordinates a curated network of contract manufacturing organizations (CMOs) including Laurus Labs in India, Nobilus Ent in Poland, SMS Lifesciences, and Anidro do Brasil, with proprietary quality oversight including annual audits and quality assurance agreements. This model is supplemented by wholly-owned affiliates: ASM Research Chemicals GmbH (Hannover) for R&D-scale synthesis of complex organic molecules and PNA monomers, and Logistics4Pharma for GDP-compliant cold chain storage and global air freight. C2 PHARMA holds an extensive portfolio of regulatory filings across the US (US-DMF), Europe (CEP), China (C-DMF), Taiwan (T-DMF), South Korea (K-DMF), Brazil, and Mexico, with several CEP approvals noted as first or second of their kind.

C2 PHARMA generates revenue through direct sales of APIs and drug products to approximately 200 pharmaceutical companies globally, including top big pharma firms, with a sales-led go-to-market focused on ophthalmic and niche API buyers. Additional revenue streams include API lifecycle management services (acquiring and managing non-core or difficult-to-manufacture APIs on behalf of pharmaceutical clients) and affiliated cold chain logistics services. Pricing is quote-based and not publicly disclosed. The company is wholly owned by founder and CEO Andrew Badrot, with no disclosed institutional venture capital or private equity backing, and operates through legal entities in Ireland, Luxembourg, the United States, Germany, and India.

C2 PHARMA firmographics

Firmographics
Name
C2 PHARMA
Legal name
C-squared PHARMA Limited / C-squared PHARMA S.à r.l.
Website
https://c2pharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
C2 PHARMA is a privately-held pharmaceutical group that manufactures and distributes niche ophthalmic and cardiac active pharmaceutical ingredients (APIs) via a virtual CMO network, serving approximately 200 pharmaceutical companies globally through direct sales and multi-jurisdiction regulatory filings.
Ownership category
akta.pro rank

C2 PHARMA industry classification

Industry
Product category
Active Pharmaceutical Ingredients
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYTLAIACAD
Pharmaceutical & Life Sciences Warehousing (GDP-Compliant)
Transportation & Logistics/Third-Party & Fourth-Party Logistics (3PL/4PL) / Contract Logistics/Warehousing Operations & Contract Storage (Dedicated/Shared)

Keywords

  • Ophthalmic APIs
  • Active pharmaceutical ingredients
  • Niche API manufacturing
  • Phytochemical APIs
  • API lifecycle management

Where C2 PHARMA is headquartered

Location

Headquarters

HQ city
Cork
HQ country
Ireland
HQ region
Europe

Offices6 records

Markets served

C2 PHARMA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Others

Revenue model

  1. API Manufacturing and Distribution: Manufacturing and distribution of active pharmaceutical ingredients (APIs) including ophthalmic APIs (atropine sulfate, bimatoprost, brimonidine tartrate, cyclopentolate hydrochloride, dorzolamide hydrochloride, homatropine hydrobromide, latanoprost, naphazoline hydrochloride, naphazoline nitrate, oxybuprocaine hydrochloride, pilocarpine hydrochloride, pilocarpine nitrate, timolol maleate, tropicamide) and cardiac APIs (digoxin, digoxin micronized). Direct sales to approximately 200 pharmaceutical companies globally.
  2. API Lifecycle Management Services: Services to streamline pharmaceutical companies' product portfolios by acquiring and managing non-core, difficult-to-manufacture, or challenging-to-distribute APIs and drug products.
  3. Cold Chain Logistics: Customized cold chain and GDP-compliant transport and storage solutions through affiliate Logistics4Pharma.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

C2 PHARMA product offering

Product offering

Core offering

C2 PHARMA manufactures and distributes Active Pharmaceutical Ingredients (APIs) and complex chemical compounds from natural and synthetic origins. The company operates a virtual manufacturing model combining contract manufacturing organizations (CMOs) with proprietary quality oversight, specializing in niche and ophthalmic APIs such as atropine sulfate, bimatoprost, digoxin, latanoprost, pilocarpine, and tropicamide for approximately 200 pharmaceutical customers globally. The company also offers API lifecycle management services and GDP-compliant cold chain logistics through affiliate Logistics4Pharma.

Product overview

C2 PHARMA is a pharmaceutical group established in 2014 that manufactures and distributes active pharmaceutical ingredients (APIs) and complex chemical compounds obtained from natural and synthetic origins. The company positions itself as a global leader in ophthalmic and niche APIs, offering 17 distinct API products including Bimatoprost, Brimonidine Tartrate, Cyclopentolate Hydrochloride, Digoxin, Dorzolamide Hydrochloride, Homatropine Hydrobromide, Homatropine Methylbromide, Latanoprost, Naphazoline Hydrochloride, Naphazoline Nitrate, Oxybuprocaine Hydrochloride, Pilocarpine Hydrochloride, Pilocarpine Nitrate, Timolol Maleate, and Tropicamide. The product portfolio spans ophthalmic APIs for glaucoma treatment and eye diagnostics, cardiac glycosides for heart conditions, and topical decongestants. Services include API Manufacturing and Distribution, API Lifecycle Management, and Pharma Logistics through affiliated company Logistics4Pharma offering GDP-compliant cold-chain transport and storage. The company maintains a direct sales presence across approximately 200 pharmaceutical customers globally including top pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Atropine Sulfate A naturally occurring phytochemical alkaloid originally identified in Atropa belladonna, used as an antidote for cholinergic drug and organophosphate poisoning, and for ophthalmic formulations as a cycloplegic pre-diagnostic agent and treatment for refractive and accommodative amblyopia. Sold to pharmaceutical manufacturers.
  • Bimatoprost A synthetic amide analogue (prostamide) of prostaglandin F2α, used as first-line treatment for glaucoma in European Glaucoma Society guidelines, as 0.03% ophthalmic solution for ocular hypertension and glaucoma, and for eyelash hypotrichosis. Sold to ophthalmic pharmaceutical manufacturers.
  • Brimonidine Tartrate A synthetic, highly selective third generation α2-adrenergic agonist used to reduce intraocular pressure through dual mechanism of reducing aqueous humour production and increasing uveoscleral outflow, approved in more than 50 countries. Sold to ophthalmic pharmaceutical manufacturers.
  • Cyclopentolate Hydrochloride A synthetic muscarinic receptor antagonist developed in the 1950s, used as first-choice drug for cycloplegic refraction and diagnostic pupil dilation in patients of all ages, on WHO List of Essential Medicines. Sold to ophthalmic pharmaceutical manufacturers.
  • Digoxin A cardiac glycoside extracted from Digitalis lanata leaves, used chronically in therapy of cardiac arrhythmias especially atrial fibrillation and heart failure, on WHO List of Essential Medicines. Sold to cardiovascular pharmaceutical manufacturers.
  • Digoxin Micronized A micronized grade of cardiac glycoside extracted from Digitalis lanata leaves, developed to meet stringent specifications for particle size distribution less than 10 μm, used for cardiac arrhythmias and heart failure treatment. Sold to cardiovascular pharmaceutical manufacturers.
  • Dorzolamide Hydrochloride A topical carbonic anhydrase inhibitor (CAI) belonging to sulfonamide derivatives, selectively inhibits carbonic anhydrase II, used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Sold to ophthalmic pharmaceutical manufacturers.
  • Homatropine Hydrobromide A synthetic analogue of atropine prepared by esterification of mandelic acid with 3α-tropine, used as 2% or 5% ophthalmic solution to induce mydriasis and cycloplegia prior to retinoscopy, with effect 10 times weaker than atropine. Sold to ophthalmic pharmaceutical manufacturers.
  • Homatropine Methylbromide A synthetic analog of atropine belonging to antimuscarinics, used to treat duodenal or stomach ulcers and intestinal problems, may be used to prevent nausea, vomiting, and motion sickness, and as sub-therapeutic amount in opioid formulations. Sold to pharmaceutical manufacturers.
  • Latanoprost A rationally designed synthetic ester prodrug analogue of prostaglandin F2α (PGF2α), on WHO List of Essential Medicines and top 100 most commonly prescribed medications in the US, used for reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension. Sold to ophthalmic pharmaceutical manufacturers.
  • Naphazoline Hydrochloride A white crystalline sympathomimetic amine compound, patented in 1934 and used primarily to relieve allergy symptoms and as decongestant, with CNS stimulant and blood vessel constrictor properties for reducing redness in minor eye irritations. Sold to pharmaceutical manufacturers.
  • Naphazoline Nitrate A white crystalline powder developed in 1942 as nasal formulation for congestion, primarily used as topical nasal decongestant but also included in ophthalmic solutions to alleviate ocular redness and irritation. Sold to pharmaceutical manufacturers.
  • Oxybuprocaine Hydrochloride A synthetic local anesthetic also known as benoxinate, first described in 1950, used in 0.4% ophthalmic solution for short ocular diagnostic and minor surgical procedures, with anesthetic activity ten times that of cocaine. Sold to ophthalmic pharmaceutical manufacturers.
  • Pilocarpine Hydrochloride An agonist of muscarinic type cholinergic receptors, isolated from jaborandi leaves, used in eye drops for glaucoma treatment and as oral tablets for dry mouth and eyes caused by Sjögren's syndrome and salivary gland hypofunction from radiotherapy. Sold to ophthalmic pharmaceutical manufacturers.
  • Pilocarpine Nitrate An agonist of muscarinic type cholinergic receptors derived from Pilocarpus microphyllus (Maranham Jaborandi), exclusive distribution by C2 PHARMA from Anidro do Brasil, used for chronic glaucoma treatment and to increase sweat secretion by iontophoresis in cystic fibrosis diagnostic devices. Sold to ophthalmic pharmaceutical manufacturers.
  • Timolol Maleate A non-selective beta-adrenergic antagonist (β1 and β2) patented in 1978, used topically to reduce intraocular pressure in open-angle glaucoma or ocular hypertension, and systemically for hypertension, myocardial infarction, arrhythmias and migraine prophylaxis. Sold to ophthalmic pharmaceutical manufacturers.
  • Tropicamide A fully synthetic non-selective muscarinic antagonist developed in the 1950s, on WHO List of Essential Medicines, used as 0.5% and 1% topical ophthalmic solution for mydriasis and cycloplegia in diagnostic procedures, and reported as diagnostic tool in Alzheimer's disease. Sold to ophthalmic pharmaceutical manufacturers.
  • API Lifecycle Management Services Comprehensive end-to-end management of APIs from development through commercial supply, including regulatory filings, manufacturing oversight, and quality control. Services streamline pharmaceutical companies' product portfolios by acquiring and managing non-core, difficult-to-manufacture, or challenging-to-distribute APIs and drug products. Targeted at pharmaceutical manufacturers.
  • GDP-Compliant Cold Chain Logistics Customized cold chain and GDP-compliant transport and storage solutions for APIs and pharmaceutical products, supporting temperature ranges of +2 to +8°C, +15 to +25°C, and -15 to -25°C. Operates 1000 m2 warehouse near Frankfurt Airport with validated temperature-controlled vehicles and IATA license for global air freight. Targeted at pharmaceutical manufacturers requiring temperature-controlled distribution.

Companies that use C2 PHARMA

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

C2 PHARMA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

C2 PHARMA partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered supporting, core and strategic.

  • SMS LifesciencessupportingImplementation/ SI/ Consulting Partner · 1 October 2023Additional CMO partner added to strengthen manufacturing network and accelerate bringing R&D portfolio of ophthalmic products to commercial market.
  • Nobilus EntcoreImplementation/ SI/ Consulting Partner · 18 March 2019Polish manufacturing partner for digoxin API acquired from Roche/Galenus Mannheim. C2 PHARMA is product owner; Nobilus is manufacturing partner and releasing entity. Provides parallel manufacturing for supply redundancy.
  • Theracule ASstrategicStrategic or Co-development Partner · 4 October 2018Strategic partnership focused on supporting Theracule's new drug development programs for rare neurodevelopmental disorders. C2 PHARMA leads seed funding and provides GMP-compliant botanical extracts and APIs, regulatory support, and analytical sciences support through ASM Research Chemicals.
  • Logistics4PharmacoreOthers · 16 October 2017Cold-chain logistics spin-off established by C2 PHARMA offering GDP-compliant transport and storage solutions for APIs and pharmaceutical products. Operates 1000 m2 warehouse near Frankfurt Airport with validated temperature-controlled vehicles and IATA license for global air freight.
  • ASM Research Chemicals GmbHcoreImplementation/ SI/ Consulting Partner · 16 October 2017R&D synthesis services company acquired by C2 PHARMA located in Hannover, Germany. Pioneer in synthesis of PNA (Peptide Nucleic Acid) Monomers and provides contract manufacturing for R&D-scale synthesis of complex organic molecules and impurities. Operates 600 m2 chemistry laboratory with 13 staff, 7 PhD chemists.
  • Anidro do Brasil ExtraçõescoreStrategic or Co-development Partner · 16 October 2017World's leading manufacturer of pilocarpine, exclusive distributor relationship with C2 PHARMA. Produces pilocarpine extracted from Jaborandi plant leaves (Pilocarpus microphyllus) native to northern Brazil.
  • Laurus LabscoreImplementation/ SI/ Consulting Partner · 2 October 2017Indian-based API manufacturer and CMO partner. C2 PHARMA invested in dedicated digoxin manufacturing facility at Laurus Labs site in Vizag, India. Investment exceeded USD 5 million for 1800 m2 facility with annual production capacity exceeding global digoxin demand.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

C2 PHARMA competitors and assessment

Company assessment

Direct peers

  • EuroAPI: European specialty small-molecule API manufacturer spun out of Sanofi, serving branded and generic pharma with complex APIs across multiple therapeutic categories. Directly comparable to C2 PHARMA's small-molecule, multi-regulatory niche API model and customer base of top pharma companies.
  • Hovione: Portugal-headquartered specialty CDMO with deep small-molecule API and ophthalmic expertise, including particle engineering for inhaled and ophthalmic dosage forms. Competes head-to-head with C2 PHARMA for complex API contracts and shares the same ophthalmic and niche-pharma customer profile.
  • Cambrex (Eurofins Discovery): Specialty small-molecule API manufacturer offering process R&D, scale-up, and commercial manufacturing across multiple therapeutic categories including ophthalmology. Operates a similar asset-and-virtual hybrid API model serving global pharma customers, comparable in product portfolio breadth and regulatory complexity.
  • Divi's Laboratories: India-headquartered API manufacturer and custom synthesis provider serving global generics and Big Pharma with complex small molecules. Comparable scale, generic/specialty API mix, US-DMF/CEP-heavy regulatory footprint, and ophthalmic API capabilities paralleling C2 PHARMA's commercial manufacturing model.
  • Piramal Pharma Solutions: Global CDMO/API division of Piramal Pharma offering small-molecule API development, tech transfer and commercial manufacturing to branded and generic pharma. Overlaps with C2 PHARMA's virtual manufacturing strategy and global pharma customer base across ophthalmic, cardiovascular and specialty molecules.
  • Laurus Labs: Indian API and formulation manufacturer that operates C2 PHARMA's dedicated digoxin facility but also sells APIs independently into global generics and Big Pharma. Overlaps in small-molecule API manufacturing, CMO services, and the same ophthalmic/contract-manufacturing competitive space.
  • Johnson Matthey Health (Veranova): Specialty API/HPAPI CDMO business (now Veranova) offering complex small-molecule development and commercial manufacturing to global pharma. Comparable complexity, regulatory intensity, and customer profile to C2 PHARMA's niche-API commercial manufacturing model.
  • Indena: Italy-headquartered specialist in botanical-derived APIs and phytochemical extracts for pharma, with deep sustainability and traceability programs for natural-source ingredients. Direct mirror of C2 PHARMA's phytochemical expertise (pilocarpine, digoxin/Digitalis, atropine) and plant-derived API positioning.
  • PolyPeptide Group: Specialty peptide and small-molecule API manufacturer serving global pharma and ophthalmic customers with regulatory-grade peptides and complex actives. Comparable in niche positioning, regulatory depth (US-DMF, CEP) and GMP manufacturing across multiple therapeutic categories.

Broad incumbents

  • Aurobindo Pharma: Large vertically integrated Indian generic manufacturer with significant ophthalmic API/formulation operations and global Big Pharma supply contracts. Competes broadly with C2 PHARMA in ophthalmic APIs but across a much wider product set and own-plant model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

C2 PHARMA social profiles

Digital presence

C2 PHARMA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

C2 PHARMA leadership team

Management profile

Number of profiles

Profiles9 records

C2 PHARMA subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

C2 PHARMA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

C2 PHARMA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C2 PHARMA

What does C2 PHARMA do?

C2 PHARMA manufactures and distributes Active Pharmaceutical Ingredients (APIs) and complex chemical compounds from natural and synthetic origins. The company operates a virtual manufacturing model combining contract manufacturing organizations (CMOs) with proprietary quality oversight, specializing in niche and ophthalmic APIs such as atropine sulfate, bimatoprost, digoxin, latanoprost, pilocarpine, and tropicamide for approximately 200 pharmaceutical customers globally. The company also offers API lifecycle management services and GDP-compliant cold chain logistics through affiliate Logistics4Pharma.

Is C2 PHARMA a public or private company?

C2 PHARMA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was C2 PHARMA founded?

C2 PHARMA was founded in 2014. It employs 11 to 50 people.

Where is C2 PHARMA based?

C2 PHARMA is headquartered in Cork, Ireland, in the Europe region.

How does C2 PHARMA make money?

Three revenue lines are on record. API Manufacturing and Distribution is the primary driver. The others are API Lifecycle Management Services and cold Chain Logistics.

Who are C2 PHARMA's main competitors?

Direct peers on record are EuroAPI, Hovione, Cambrex (Eurofins Discovery), Divi's Laboratories, Piramal Pharma Solutions, Laurus Labs, Johnson Matthey Health (Veranova), Indena and PolyPeptide Group. Aurobindo Pharma is listed as a broad incumbent.

Does C2 PHARMA have an API?

No public API is recorded for C2 PHARMA.

What industry is C2 PHARMA in?

C2 PHARMA's product category is Active Pharmaceutical Ingredients. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals